Orexigen Announces Upcoming Data Presentations from the Open-Label Contrave Ignite Study at the Annual Meeting of the American Diabetes Association

By: via Benzinga
Orexigen Therapeutics (NASDAQ: OREX) announced today that two Contrave® (naltrexone HCI and bupropion HCI) abstracts will be presented ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.